Focal Lesion in the Splenium of the Corpus Callosum in Epileptic Patients: Antiepileptic Drug Toxicity?

References

1. ↵
   Chason DP, Fleckenstein JL, Ginsburg ML, Mendelsohn DB, Mathews D. Transient splenial edema in epilepsy: MR imaging evaluation. Presented at the annual meeting of the American Society of Neuroradiology; June 21–27, 1996; Seattle, WA
2. ↵
   Georgy BA, Hesselink JR, Jernigan TL. MR imaging of the corpus callosum. AJR Am J Roentgenol 1993;160:949-955

   CrossRefPubMedWeb of Science
3. ↵
   Kieburtz KD, Ketonen L, Zettelmaier AE, Kido D, Caine ED, Simon JH. MRI findings in HIV cognitive impairment. Arch Neurol 1990;47:643-645

   CrossRefPubMedWeb of Science
4. Chang KH, Cha SH, Han MH, Park SH, Nah DL, Hong JH. Marchiafava-Bignami disease: serial changes in corpus callosum on MRI. Neuroradiology 1992;34:480-482

   CrossRefPubMedWeb of Science
5. ↵
   Tobita M, Mochizuki H, Takahashi S, Onoderma H, Itoyama Y, Iwasaki Y. A case of Marchiafava-Bignami disease with complete recovery: sequential imaging documenting improvement of callosal lesions. Tohoku J Exp Med 1997;182:175-179

   CrossRefPubMed
6. ↵
   Rumack CM, Guggenheim MA, Fasules JW, Burdick D. Transient positive computed tomographic scan. J Pediatr 1980;48:866-869
7. Jamakumar PN, Taly AB, Mohan PK. Transient computerizes tomographic abnormalities following partial seizure. Acta Neurol Scand 1985;72:26-29

   PubMedWeb of Science
8. Kramer RE, Luders H, Lesser RP, et al. Transient focal abnormalities of neuroimaging studies during focal status epilepticus. Epilepsia 1987;28:528-532

   PubMedWeb of Science
9. Henry TR, Drury I, Brunberg JA, Pennel PB, McKeever PE, Beydoun A. Focal cerebral magnetic resonance changes associated with partial status epilepticus. Epilepsia 1994;35:35-41

   CrossRefPubMedWeb of Science
10. Tien RD, Felsberg GJ. The hippocampus in status epilepticus: demonstration of signal intensity and morphologic changes with sequential fast spin-echo MR imaging. Radiology 1995;194:249-256

    CrossRefPubMedWeb of Science
11. ↵
    Ziegler DK. Toxicity to the nervous system of diphenylhydantoin: a review. Int J Neurol 1978;11:383-400

    PubMed
12. Ramirez JA, Mendell JR, Warmolts JR, Griggs RC. Phenytoin neuropathy: structural changes in the sural nerve. Ann Neurol 1986;19:162-167

    CrossRefPubMedWeb of Science
13. ↵
    Graham DI, Lantos PL. Greenfield's Neuropathology 6th ed. London: Arnold; 1997:624
14. ↵
    Butler WH, Ford GP, Newberne JW. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol 1987;15:143-148

    PubMedWeb of Science
15. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989;27(Suppl 1):43S-45S
16. Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, Newberne JW. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225-238

    PubMedWeb of Science
17. ↵
    Weiss KL, Schroeder CE, Kastin SJ, et al. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology 1994;44:1944-1949

    Abstract/FREE Full Text
18. Pederson B, Hojgaard K, Dam M. Vigabatrin: no microvacuolation in a human brain. Epilepsy Res 1987;1:74-76

    CrossRefPubMedWeb of Science
19. Agosti R, Yasargil G, Egil M, et al. Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles. Epilepsy Res 1990;6:166-170

    CrossRefPubMedWeb of Science
20. ↵
    Luders HN. Epilepsy Surgery New York: Raven; 1992;353-354